Combretastatin A4 Prodrug : OXiGENE : Angiogenesis inhibitor

Combretastatin (EurekAlert)
Press release announcing results of Phase I Combretastatin A4 phosphate trials trials in solid tumors. Results of the trial conducted by researchers at the University of Pennsylvania Cancer Center showed that patients with solid cancerous tumors were able to safely tolerate combretastatin. [4/00]